MAP2K7 and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome: Our data highlights the potential of BET/MEK combinations in a broad range of tumors, including SCLC, TNBC, and PaCa, where patients have few treatment options.